Detalhe da pesquisa
1.
Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis.
Haematologica
; 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38299578
2.
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study.
Lancet Oncol
; 23(3): 416-427, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35151415
3.
A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma.
Blood
; 134(2): 123-133, 2019 07 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30862646
4.
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
Lancet
; 394(10214): 2096-2107, 2019 12 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31735560
5.
Isatuximab: Nursing Considerations for Use in the Treatment of Multiple Myeloma.
Clin J Oncol Nurs
; 25(6): 706-712, 2021 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34800109
6.
Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma.
Leukemia
; 35(12): 3526-3533, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34050260